Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs

Table 3

Dynamic blood glucose profile of patients with different HbA1c stratification before and after treatment.

	Baseline		4 weeks after treatment		Δ
	High-A1C (≥7%)	Low-A1C (<7%)	High-A1C (≥7%)	Low-A1C (<7%)	High-A1C (≥7%)	Low-A1C (<7%)
24 h MBG
MAGE
TIR (%)
TAR (%)	24.83 (12.76, 43.15)	0.00 (0.00, 16.93)	9.72 (0.00, 25.70)	0.70 (0.00, 12.76)	-17.54 (-29.08, -3.38)	0.52 (-4.17, 3.22)
TBR (%)	0.00 (0.00, 1.74)	0.00 (0.00, 0.00)	0.00 (0.00, 1.65)	0.00 (0.00, 0.35)	0.00 (-1.74, 1.39)	0.00 (0.00, 0.35)
AUC3.9-10
	26.48 (5.41, 70.53)	0.00 (0.00, 9.32)	6.89 (0.00, 28.58)	0.10 (0.00, 7.03)	-12.37 (-52.96, 0.15)	0.00 (-6.57, 5.20)
	0.00 (0.00, 0.47)	0.00 (0.00, 0.00)	0.00 (0.00, 0.23)	0.00 (0.00, 0.02)	0.00 (-0.47, 0.11)	0.00 (0.00, 0.02)
HBGI
LBGI	0.45 (0.01, 3.03)	0.89 (0.00, 1.57)	1.30 (0.39, 3.24)	0.51 (0.19, 1.64)
GMI

; . 24 h MBG: 24-hour mean blood glucose; MAGE: 24-hour mean amplitude of glycemic excursion; TIR: time-in-range (3.9-10 mmol/L); TAR: time-above-target range (>10 mmol/L); TBR: time-below-target ranges (<3.9 mmol/L); AUC3.9-10: the incremental area under the curve of the glucose level between 3.9 and 10 mmol/L; : the incremental area under the curve of the glucose level more than 10 mmol/L; : the incremental area under the curve of the glucose level less than 3.9 mmol/L; HBGI: high blood glucose index; LBGI: low blood glucose index; GMI: glucose management indicator.